Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.54 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5294238 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL5306836 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL30569522 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL10717990 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL1249217 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL8752673 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL5597191 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL4104862 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL2905602 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| Dodine SCHEMBL21643 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587176-A2 | POLYGUANIDINE-CONTAINING MEMBRANES AND METHODS OF USING THEREOF | Ohio State Innovation Foundation (US) | 2025-07-23 | — | — | EP | claimed |
| WO-2024059033-A2 | POLYGUANIDINE-CONTAINING MEMBRANES AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-03-21 | — | — | WO | claimed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | claimed |
| US-20210379087-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2021-12-09 | — | — | US | claimed |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-23 | — | — | US | claimed |
| CN-113347969-A | Composition for eliminating senescent cells | 维也纳自然资源与生命科学大学 | 2021-09-03 | — | — | CN | claimed |
| US-20210186906-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-24 | — | — | US | claimed |
| EP-3643305-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | Universität für Bodenkultur Wien (AT) | 2020-04-29 | — | — | EP | claimed |
| CN-111019121-A | Preparation method of guanidine polymer ionic liquid | 石家庄学院 | 2020-04-17 | — | — | CN | claimed |
| US-9603817-B2 | Methods, compositions, and kits for treating pain and pruritis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-28 | — | — | US | claimed |
| JP-2011513484-A | — | — | 2011-04-28 | — | — | JP | claimed |
| US-20110086818-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITUS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2011-04-14 | — | — | US | claimed |
| WO-2011006073-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-01-13 | — | — | WO | claimed |
| EP-2271329-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | President and Fellows of Harvard College (US) | 2011-01-12 | — | — | EP | claimed |
| US-20100099772-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | claimed |
| EP-2101819-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-23 | — | — | EP | claimed |
| WO-2009114139-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-17 | — | — | WO | claimed |
| WO-2008063603-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-05-29 | — | — | WO | claimed |
| EP-0507317-A2 | Biguanide derivatives, manufacturing method thereof, and disinfectants containing the derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-07 | — | — | EP | claimed |
| US-4487826-A | EXCELLENT SHELF LIFE AND HEAT SENSITIVITY | TOPPAN PRINTING CO., LTD. (JP) | 1984-12-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086818-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITUS | TRPV1, OPRL1, ITCH | MEN1 4441/4885CYP1A2 4784/4885KMT2A 2820/4885 |
| US-20100099772-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | TRPV1, TRPV2, TRPV3 | MEN1 3223/4885CYP1A2 4640/4885KMT2A 2886/4885 |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | MEN1 2018/4885CYP1A2 4646/4885KMT2A 2190/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | MEN1 1897/4885CYP1A2 4639/4885KMT2A 2196/4885 |
| US-20210186906-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | TRPV1, TRPV2, TRPV3 | MEN1 3223/4885CYP1A2 4640/4885KMT2A 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.